Dipeptidyl Peptidase-4 Inhibitor-Related Bullous Pemphigoid: Clinical, Laboratory, and Histological Features, and Possible Pathogenesis

Dipeptidyl peptidase-4 inhibitor (DPP4i) is a widely used antidiabetic agent. Emerging cases of DPP4i-associated bullous pemphigoid (DBP), whose pathogenesis remains unclear, have been reported. Thus, a retrospective study was conducted from January 2016 to June 2021 to determine the clinical, labor...

Descripción completa

Detalles Bibliográficos
Autores principales: Hung, Chih-Tsung, Chang, Yung-Lung, Wang, Wei-Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9692886/
https://www.ncbi.nlm.nih.gov/pubmed/36430582
http://dx.doi.org/10.3390/ijms232214101

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9692886/
https://www.ncbi.nlm.nih.gov/pubmed/36430582
http://dx.doi.org/10.3390/ijms232214101

Ejemplares similares